Sunday, December 30, 2007

MILNACIPRAN AND FIBROMYALGIA


Milnacipran is described as the first in a new class of antidepressants, agents that act as both norepinephrine (noradrenaline) and serotonin reuptake inhibitors (NSRIs).

Exciting information about fibromyalgia (FM) pathophysiology, clinical aspects, and emerging treatment options was presented at this year's American College of Rheumatology (ACR) 71st Annual Meeting. This information further confirms the role of CNS dysregulation in the etiology of the condition and the beneficial effect of emerging neuromodulatory agents on various symptom domains of FM.
Milnacipran is a serotonin-norepinephrine reuptake inhibitor that augments the function of these 2 neurotransmitters, yielding improvement in pain through facilitation of antinociceptive pain signaling in the CNS.[...]

Posted by Antonio Howell, M.D. at 12/30/2007 07:22:00 AM

Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Disclaimer:

This publications contains the opinions and ideas of its author(s). It is intended to provide helpful and informative material on the subjects addressed. It is written with the understanding that the author(s) is (are) not engaged in rendering medical, health, or any other kind of professional service(s). The reader should consult his or her medical, health or other competent professional before adopting any of the suggestions. The author(s) specifically disclaim all responsibility for any liability, loss, or risk, personal or otherwise, which is incurred as a consequence, directly or indirectly, of the use and application of any of the contents of this site.